Introduction {#Sec1}
============

Chronic hepatitis C virus (HCV) infection is one of the major causes of chronic liver diseases such as cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC)^[@CR1]^. The goal of antiviral treatment of chronic hepatitis C (CHC) is eradication of HCV to prevent fibrosis progression and the development of liver-related and non-liver-related complications, leading to prolonged survival^[@CR2]--[@CR4]^. In a meta-analysis, HCV eradication by interferon (IFN)-based antiviral treatment was shown to directly reduce HCC risk^[@CR5]^. The introduction of new direct-acting antivirals (DAAs) for the treatment of CHC has derived excellent sustained virological response (SVR) rates in most HCV-infected patients, including patients with advanced fibrosis and extrahepatic comorbidities. Current international guidelines recommend antiviral treatment for all patients with HCV-related chronic liver disease, except those with limited life expectancy owing to non-liver-related comorbidities^[@CR2]--[@CR4]^. Although the earlier studies demonstrated that DAA-induced SVR has little or no impact on the risk of developing HCC and even reported early occurrence and recurrence of HCC in virologically cured patients with DAA-based treatments^[@CR6]--[@CR10]^, recent studies using the US Veterans Administration database determined the significant association between DAA-induced SVR and reduction in the risk of HCC^[@CR11],[@CR12]^. Moreover, SVR was associated with a reduced risk of HCC irrespective of type of antiviral treatments (either IFN-based therapy or DAA-based therapy)^[@CR12]^.

Patients with advanced hepatic fibrosis are at increased risk of developing hepatic decompensation or HCC within a relatively short timeframe^[@CR13],[@CR14]^, and the risk can be substantially reduced by successful HCV eradication^[@CR15]--[@CR17]^. Therefore, antiviral therapies must be initiated immediately in these patients if not contraindicated^[@CR2]--[@CR4]^. Although numerous studies have found the clinical benefits of antiviral therapy in patients with advanced liver disease^[@CR5],[@CR15],[@CR18]--[@CR20]^, direct evidence supporting antiviral treatment initiation at earlier stages of fibrosis is scarce. While the risk of developing hepatic decompensation, HCC, or death has been reported to be significantly lower in patients with METAVIR fibrosis grades F0--F2^[@CR13],[@CR14]^, higher SVR rates are achievable and liver disease progression can be halted after SVR achievement in patients with lower-stage fibrosis, augmenting treatment benefits^[@CR2]^. In this study, we aimed to analyse the association between eradication of HCV and the risk of HCC development and all-cause mortality in HCV-infected patients according to fibrosis stage of liver.

Results {#Sec2}
=======

Study population {#Sec3}
----------------

Among 1,373 patients with chronic HCV infection included in the final analyses, 629 patients were not treated (the untreated group), 122 received antiviral treatment but failed to achieve SVR (the non-SVR group), and remaining 622 were treated and achieved SVR (the SVR group). Among 744 treated patients, 418 patients were treated with IFN-based therapy and 326 with DAAs. Patients treated with DAAs received daclatasvir/asunaprevir (*n* = 198) or elbasvir/grazoprevir (*n* = 4) for patients infected by genotype 1B HCV, sofosbuvir/ledipasvir (*n* = 39) or daclatasvir/sofosbuvir (*n* = 9) for patients infected by genotype 1 A HCV and genotype 1B HCV with resistance-associated variants (i.e., L31W/V/F/N/I/S/P/R and Y93N/H/C/P/D variants), or sofosbuvir plus ribavirin (*n* = 76) for patients infected by genotype 2 HCV. The median duration of follow-up was 3.5 (interquartile range \[IQR\], 1.9--6.6) years: 4.2 (IQR, 2.0--7.4) years in the untreated group, 5.6 (IQR, 3.1--7.4) years in the non-SVR group, and 2.5 (IQR, 1.8--5.8) years in the SVR group. Table [1](#Tab1){ref-type="table"} shows the baseline demographic and clinical characteristics of the study patients by group. The median age was 58 (IQR, 51--67) years overall, and was not significantly different between the groups (*P* = 0.33). Male patients accounted for 40.5%, and almost all patients were infected with HCV genotype 1 or 2. Prothrombin time was significantly longer in the non-SVR group and HCV viral load differed significantly between the groups (*P* = 0.03 and *P* \< 0.001, respectively). While platelet count and serum ALT level differed between the groups, the differences were not statistically significant (*P* = 0.09 and *P* = 0.07, respectively).Table 1Baseline characteristics by group.CharacteristicsOverallUntreatedTreated without SVRTreated with SVR*P* value(*N* = 1373)(*n* = 629)(*n* = 122)(*n* = 622)Age, median (IQR), y58 (51--67)59 (51--67)58 (50--65)58 (50--68)0.33Male556 (40.5)258 (41.0)52 (42.6)246 (39.5)0.77Genotype (*n* = 1344)0.10  1742 (55.2)346 (57.1)70 (58.3)326 (52.8)  2582 (43.3)250 (41.3)46 (38.3)286 (46.3)  Other20 (1.5)10 (1.7)4 (3.3)6 (1.0)Laboratory data, median (IQR)  Platelet count, × 10^9^/L (*n* = 1204)166 (127--208)173 (128--214)153 (114--207)165 (128--203)0.09  Albumin, g/dL (*n* = 1239)4.2 (4.0--4.4)4.2 (4.0--4.4)4.1 (3.9--4.3)4.2 (4.0--4.4)0.76  Total bilirubin, mg/dL *(n* = 1239)0.8 (0.6--1.1)0.8 (0.6--1.1)0.9 (0.7--1.1)0.8 (0.7--1.1)0.69  ALT, IU/L (*n* = 1242)52 (28--97)46 (27--82)56 (30--97)59 (29--107)0.07  AST, IU/L (*n* = 1242)53 (33--83)48 (31--77)54 (34--80)56 (34--92)0.12  GGT, U/L (*n* = 986)42 (24--78)43 (24--80)50 (29--77)40 (23--77)0.17  International normalised ratio (*n* = 973)1.03 (0.98--1.09)1.04 (0.98--1.09)1.05 (0.99--1.12)1.02 (0.97--1.08)0.03  AFP, ng/mL (*n* = 1343)5.0 (3.2--9.0)5.0 (3.0--9.0)5.1 (3.8--10.0)5.0 (3.4--8.6)0.70  HCV RNA, log~10~ IU/mL (*n* = 1272)6.03 (5.37--6.43)5.98 (5.29--6.37)6.41 (6.03--6.65)6.03 (5.34--6.43)\<0.001APRI (*n* = 1196)0.27  \<0.5357 (29.8)150 (32.9)30 (24.6)177 (28.6)  ≥0.5 to \<1.5519 (43.4)193 (42.3)60 (49.2)266 (43.0)  ≥1.5320 (26.8)113 (24.8)32 (26.2)175 (28.3)FIB-4 (*n* = 1196)0.63  \<1.45258 (21.6)108 (23.7)26 (21.3)124 (20.1)  ≥1.45 to \<3.25492 (41.1)185 (40.6)47 (38.5)260 (42.1)  ≥3.25446 (37.3)163 (35.7)49 (40.2)234 (37.9)Diabetes mellitus208 (15.1)102 (16.2)21 (17.2)85 (13.7)0.36Hypertension247 (18.0)110 (17.5)22 (18.0)115 (18.5)0.90Antiviral treatment regimen (*n* = 744)\<0.001  IFN-based therapy418 (56.2)---104 (85.2)314 (50.5)  DAA therapy326 (43.8)---18 (14.8)308 (49.5)Unless otherwise indicated, data are given as number (%) of patients.

Association between SVR and the risk of HCC occurrence {#Sec4}
------------------------------------------------------

Eighty-five patients (6.2%) developed HCC during the observation period: 59 (9.4%) in the untreated group, 11 (9.0%) in the non-SVR group, and 15 (2.4%) in the SVR group, corresponding to 5-year cumulative incidences of 12.3%, 12.4%, and 4.6%, respectively (Table [2](#Tab2){ref-type="table"}). There was a significant difference in the cumulative risk of HCC development between the groups (*P* \< 0.001 by log-rank test) (Fig. [1A](#Fig1){ref-type="fig"}). Multivariable Cox proportional hazards regression analysis revealed that SVR achieved with treatment was associated with a significantly lower risk of HCC occurrence (*vs*. untreated; adjusted hazard ratio \[HR\], 0.165; 95% confidence interval \[CI\], 0.077--0.350; *P* \< 0.001) (Table [3](#Tab3){ref-type="table"}). Male gender and higher levels of total bilirubin, international normalised ratio, and FIB-4 were significantly associated with an increased risk of HCC development in multivariable analysis. The HRs of antiviral treatment for HCC development were estimated in the subgroups according to baseline characteristics, the association between treatment and a reduced risk of HCC was verified in most subgroups (Fig. [2](#Fig2){ref-type="fig"}). Among 85 patients who were diagnosed with HCC during the observation period, 74 patients (87.1%) were diagnosed as the Barcelona Clinic for Liver Cancer stage 0 or A, and the distributions of stage at the diagnosis of HCC were similar among the three groups (*P* = 0.09) since most of the included patients underwent regular check-up.Table 2Clinical events by group.OutcomesOverallUntreatedTreated without SVRTreated with SVR***Overall*Hepatocellular carcinoma**1-yearRate, %**0**.**71**.**300**.**3**Sample size12205181155873-yearRate, %**4**.**75**.**86**.**92**.**8**Sample size547285661965-yearRate, %**9**.**512**.**312**.**44**.**6**Sample size29414339110**All-cause mortality**1-yearRate, %**0**.**10**.**200**.**2**Sample size12985671216103-yearRate, %**1**.**31**.**700**.**9**Sample size752398922625-yearRate, %**2**.**94**.**61**.**10**.**9**Sample size507258681817-yearRate, %**6**.**19**.**84**.**60**.**9**Sample size31017038102***FIB-4* \< *1***.***45*Hepatocellular carcinoma**1-yearRate, %**0**.**4000**.**8**Sample size22986251183-yearRate, %**1**.**21**.**900**.**8**Sample size1094714485-yearRate, %**1**.**21**.**900**.**8**Sample size4717723**All-cause mortality**1-yearRate, %**0000**Sample size24295251123-yearRate, %**0000**Sample size1556419725-yearRate, %**0000**Sample size1014213467-yearRate, %**1**.**33**.**100**Sample size56261020***FIB-4* ≥ *1***.***45 to* \< *3***.***25*Hepatocellular carcinoma**1-yearRate, %**0**.**20**.**600**Sample size440150452453-yearRate, %**2**.**64**.**63**.**30**.**7**Sample size1837226855-yearRate, %**4**.**77**.**98**.**20**.**7**Sample size106401749**All-cause mortality**1-yearRate, %**0**.**2000**.**4**Sample size462161472543-yearRate, %**1**.**92**.**501**.**8**Sample size244103331085-yearRate, %**3**.**34**.**73**.**01**.**8**Sample size1696625787-yearRate, %**5**.**68**.**68**.**41**.**8**Sample size100421444**FIB-4 ≥ 3**.**25Hepatocellular carcinoma**1-yearRate, %**1**.**74**.**200**.**4**Sample size295130431953-yearRate, %**8**.**69**.**413**.**96**.**7**Sample size1556826575-yearRate, %**18**.**022**.**622**.**312**.**3**Sample size88331540**All-cause mortality**1-yearRate, %**0000**Sample size425146492303-yearRate, %**1**.**11**.**800**.**5**Sample size21910040795-yearRate, %**4**.**69**.**800**.**5**Sample size1466130557-year**Rate**, **%8**.**717**.**73**.**40**.**5**Sample size86351437Figure 1Incidence of HCC by group. (**A**) In the entire study population. (**B**) In patients with low-probability of significant fibrosis (FIB-4 \< 1.45). (**C**) In patients with intermediate-probability of significant fibrosis (FIB-4 1.45--3.25). (**D**) In patients with high-probability of significant fibrosis (FIB-4 ≥ 3.25).Table 3Univariable and multivariable analysis of the clinical factors predictive of HCC development and all-cause mortality.HCC developmentAll-cause mortalityUnivariable analysisMultivariable analysisUnivariable analysisMultivariable analysisHazard ratio (95% CI)P valueAdjusted hazard ratio (95% CI)P valueHazard ratio (95% CI)P valueAdjusted hazard ratio (95% CI)P valueAge, y1.058 (1.035--1.082)\<0.0011.064 (1.034--1.095)\<0.001Male2.282 (1.471--3.541)\<0.0012.261 (1.268--4.032)0.0091.898 (1.064--3.387)0.03Genotype0.060.09  11 \[Reference\]1 \[Reference\]  20.572 (0.359--0.913)0.020.687 (0.371--1.274)0.23Other0.469 (0.065--3.396)0.452.567 (0.773--8.525)0.12Platelet count, ×10^9^/L0.983 (0.979--0.988)\<0.0010.99 (0.984--0.996)\<0.001Albumin, g/dL0.157 (0.093--0.263)\<0.0010.109 (0.054--0.219)\<0.0010.144 (0.065--0.319)\<0.001Total bilirubin, mg/dL2.766 (1.733--4.414)\<0.0012.051 (1.122--3.75)0.032.758 (1.432--5.311)0.0023.483 (1.657--7.318)\<0.001ALT, IU/L0.997 (0.994--1.001)0.120.996 (0.991--1.001)0.11AST, IU/L1.001 (0.999--1.004)0.241 (0.994--1.005)0.95GGT, IU/L1.003 (1.001--1.005)\<0.0011.002 (1--1.005)0.0471.002 (0.999--1.005)0.15INR5.937 (2.313--15.235)\<0.0016.331 (1.409--28.454)0.0112.666 (4.633--34.628)\<0.001AFP, ng/mL1 (0.999--1.001)0.991.000 (0.999--1.001)0.95HCV RNA, log^10^ IU/ml0.892 (0.707--1.126)0.340.906 (0.663--1.239)0.54APRI\<0.0010.21  \<0.51 \[Reference\]1 \[Reference\]  ≥0.5 to \<1.51.91 (0.816--4.473)0.141.569 (0.608--4.047)0.35  ≥1.55.133 (2.286--11.525)\<0.0012.278 (0.882--5.883)0.09FIB-4\<0.0010.0020.02  \<1.451 \[Reference\]1 \[Reference\]1 \[Reference\]  ≥1.45 to \<3.254.377 (1.011--18.951)0.052.403 (0.54--10.692)0.258.155 (1.072--62.021)0.04  ≥3.2514.057 (3.413--57.896)\<0.0015.814 (1.368--24.709)0.0213.861 (1.864--103.07)0.01Diabetes mellitus  No1 \[Reference\]1 \[Reference\]  Yes2.008 (1.244--3.241)0.0041.79 (0.931--3.44)0.08Hypertension  No1 \[Reference\]1 \[Reference\]  Yes1.256 (0.746--2.115)0.391.21 (0.585--2.499)0.61Treatment\<0.001\<0.001\<0.001\<0.001Untreated1 \[Reference\]1 \[Reference\]1 \[Reference\]1 \[Reference\]Treated wihout SVR0.733 (0.385--1.397)0.350.658 (0.313--1.383)0.270.314 (0.097--1.016)0.050.099 (0.013--0.731)0.02Treated wih SVR0.304 (0.172--0.537)\<0.0010.165 (0.077--0.35)\<0.0010.173 (0.068--0.44)\<0.0010.146 (0.05--0.424)\<0.001*P* values were determined using Cox proportional hazards regression models. *P* \< 0.05 indicated a significant difference.Variables in the multivariable analysis were selected using stepwise regression with the forward selection method.Figure 2The risk of HCC in the subgroups stratified according to baseline characteristics. The graph shows the estimates of the HR for each subgroup as a *square* (which is sized proportionally to the amount of information per subgroup) and the *horizontal lines* indicate 95% CIs, those were calculated using the Cox proportional hazards model. The *vertical solid line* at the HR of unity corresponds to the line of no effect, the HR values less than unity mean a reduced risk of developing HCC by antiviral treatment. The *diamond* indicates HR with 95% CI for all study subjects and the *vertical dashed line* depicts the overall effect. Patients who received antiviral treatment were included in the treated group regardless of SVR achievement.

When patients were categorised into the three subgroups according to the probabilities of significant hepatic fibrosis (Tables [S1](#MOESM1){ref-type="media"}), 2 of 258 patients (0.8%) with low-probability of significant fibrosis (FIB-4 \< 1.45), 16 of 492 patients (3.3%) with intermediate-probability (FIB-4 1.45--3.25), and 42 of 446 patients (9.4%) with high-probability (FIB-4 ≥ 3.25) developed HCC during follow-up, which corresponded to the 5-year cumulative risks of HCC of 1.2%, 4.7%, and 18.0%, respectively (Table [2](#Tab2){ref-type="table"}). The risk of developing HCC rose with increasing FIB-4 scores at baseline (*P* \< 0.001) (Fig. [S1A](#MOESM1){ref-type="media"}). The cumulative incidences of HCC did not differ significantly between the groups among the subgroup of low-probability of significant fibrosis (*vs*. untreated; adjusted HR, 0.884; 95% CI, 0.044--17.637; *P* = 0.94) (Table [4](#Tab4){ref-type="table"} and Fig. [1B](#Fig1){ref-type="fig"}), whereas the cumulative incidences of HCC were significantly lower in the SVR group among the subgroups of intermediate-probability (*vs*. untreated; adjusted HR, 0.171; 95% CI, 0.051--0.578; *P* = 0.004) and high-probability (*vs*. untreated; adjusted HR, 0.243; 95% CI, 0.107--0.551; *P* \< 0.001) (Table [4](#Tab4){ref-type="table"} and Fig. [1C,D](#Fig1){ref-type="fig"}).Table 4Association between SVR and the risk of HCC among subgroups according to the probabilities of significant fibrosis.HCC developmentAll-cause mortalityAdjusted hazard ratio (95% CI)*P* valueAdjusted hazard ratio (95% CI)*P* value***FIB-4 \< 1***.***45***Untreated1 \[Reference\]1 \[Reference\]Treated without SVR1.307 (0.019--90.273)0.900.970 (0.006--152.889)0.99Treated with SVR0.884 (0.044--17.637)0.940.296 (0.002--46.728)0.64***FIB-4 ≥ 1***.***45 to \< 3***.***25***Untreated1 \[Reference\]1 \[Reference\]Treated without SVR0.124 (0.016--0.939)0.040.817 (0.172--3.89)0.8Treated with SVR0.171 (0.051--0.578)0.0040.574 (0.165--1.995)0.38***FIB-4 ≥ 3***.***25***Untreated1 \[Reference\]1 \[Reference\]Treated without SVR0.928 (0.43--2.002)0.850.104 (0.014--0.783)0.03Treated with SVR0.243 (0.107--0.551)\<0.0010.057 (0.007--0.431)0.006*P* values were determined using multivariable Cox proportional hazards regression models.

After balancing baseline characteristics by means of IPW, baseline characteristics became well balanced between the groups (Tables [S2](#MOESM1){ref-type="media"}--[S8](#MOESM1){ref-type="media"}). The association of SVR with a reduced risk of HCC was confirmed in the entire cohort (*vs*. untreated; adjusted HR, 0.226; 95% CI, 0.099--0.521; *P* \< 0.001) and in the subgroups of intermediate-probability (*vs*. untreated; adjusted HR, 0.033; 95% CI, 0.002--0.706; *P* = 0.03) and high-probability (*vs*. untreated; adjusted HR, 0.305; 95% CI, 0.126--0.739; *P* = 0.009) of significant fibrosis (Tables [S9](#MOESM1){ref-type="media"}--[S10](#MOESM1){ref-type="media"} and Fig. [S2](#MOESM1){ref-type="media"}).

Association between SVR and the risk of all-cause mortality {#Sec5}
-----------------------------------------------------------

Forty-eight deaths occurred in the entire cohort during the follow-up: 40 (6.4%) in the untreated group, 3 (2.5%) in the non-SVR group, and 5 (0.8%) in the SVR group. Among 28 patients whose causes of death were identified, 26 died of liver-related complications, including HCC, and the two remaining deaths were not liver-related. No significant difference was observed among the three groups (P = 0.11 by log-rank test) when overall survival was analysed after the HCC diagnosis. Causes of non-liver-related death were extrahepatic malignancy (*n* = 1) and advanced pulmonary disease (*n* = 1). The 5-year cumulative all-cause mortality rate was 2.9% overall, and differed significantly between the groups: 4.6%, 1.1%, and 0.9% in the untreated, the non-SVR, and the SVR group, respectively (*P* \< 0.001 by log-rank test) (Table [2](#Tab2){ref-type="table"} and Fig. [3A](#Fig3){ref-type="fig"}). Table [3](#Tab3){ref-type="table"} shows independent predictive factors associated with all-cause mortality in the entire study population, in which SVR achieved with antiviral treatment was a predictive factor for a reduced risk of overall death selected by multivariable analysis (*vs*. untreated; adjusted HR, 0.146; 95% CI, 0.050--0.424; *P* \< 0.001). Subgroup analyses demonstrated that the association between treatment and improved mortality remained statistically significant in most subgroups (Fig. [4](#Fig4){ref-type="fig"}).Figure 3Incidence of all-cause mortality by group. (**A**) In the entire study population. (**B**) In patients with low-probability of significant fibrosis (FIB-4 \< 1.45). (**C**) In patients with intermediate-probability of significant fibrosis (FIB-4 1.45--3.25). (**D**) In patients with high-probability of significant fibrosis (FIB-4 ≥ 3.25).Figure 4The risk of all-cause mortality in the subgroups stratified according to baseline characteristics. The graph shows the estimates of the HR for each subgroup as a *square* (which is sized proportionally to the amount of information per subgroup) and the *horizontal lines* indicate 95% CIs, those were calculated using the Cox proportional hazards model. The *vertical solid line* at the HR of unity corresponds to the line of no effect, the HR values less than unity mean a reduced risk of all-cause mortality by antiviral treatment. The *diamond* indicates HR with 95% CI for all study subjects and the *vertical dashed line* depicts the overall effect. Patients who received antiviral treatment were included in the treated group regardless of SVR achievement.

One patient (0.4%), 14 patients (2.8%), and 21 patients (4.7%) among patients with low-, intermediate-, and high-probability of significant fibrosis died during the observation period, respectively, with the corresponding cumulative 5-year mortality rates of 0%, 3.3%, and 4.6%, respectively (Table [2](#Tab2){ref-type="table"}). The cumulative mortality rates varied significantly by fibrosis stage assessed using FIB-4 scores (*P* = 0.003) (Fig. [S1B](#MOESM1){ref-type="media"}). While the cumulative incidence rates of overall death were not significantly different between the groups among the subgroups of low-probability (*vs*. untreated; adjusted HR, 0.296; 95% CI, 0.002--46.728; *P* = 0.64) and intermediate-probability (*vs*. untreated; adjusted HR, 0.574; 95% CI, 0.165--1.995; *P* = 0.38) of significant fibrosis (Table [4](#Tab4){ref-type="table"} and Fig. [3B,C](#Fig3){ref-type="fig"}), a statistically significant difference was identified among the subgroup of high-probability (*vs*. untreated; adjusted HR, 0.057; 95% CI, 0.007--0.431; *P* = 0.006) (Table [4](#Tab4){ref-type="table"} and Fig. [3D](#Fig3){ref-type="fig"}).

After IPW, the patients in the SVR group were at significantly lower risk of mortality in the overall population (*vs*. untreated; adjusted HR, 0.171; 95% CI, 0.051--0.577; *P* = 0.004) and in the subgroup of high-probability of significant fibrosis (*vs*. untreated; adjusted HR, 0.033; 95% CI, 0.002--0.683; *P* = 0.03) (Tables [S9](#MOESM1){ref-type="media"}--[S10](#MOESM1){ref-type="media"} and Fig. [S3](#MOESM1){ref-type="media"}).

Association of type of antiviral treatment regimen with the risk of HCC and all-cause mortality {#Sec6}
-----------------------------------------------------------------------------------------------

Among 622 patients who achieved SVR with antiviral treatment, 314 patients received IFN-based therapy and 308 received DAA therapy. As expected, patients treated with DAA therapy were older and showed lower platelet count and serum albumin level, and higher FIB-4 scores compared with patients treated with IFN-based therapy (Table [S11](#MOESM1){ref-type="media"}). The difference in the cumulative risk of HCC development between the groups was significant (*P* = 0.006 by log-rank test) (Fig. [S4A](#MOESM1){ref-type="media"}), while the difference in the cumulative risk of overall death was not (*P* = 0.45 by log-rank test) (Fig. [S4B](#MOESM1){ref-type="media"}). However, type of antiviral agent that induced SVR was not associated with HCC risk (*vs*. IFN-based therapy; adjusted HR, 4.289; 95% CI, 0.648--28.408; *P* = 0.13) and the risk of all-cause mortality (*vs*. IFN-based therapy; adjusted HR, 1.348; 95% CI, 0.208--8.735; *P* = 0.75) in the multivariable Cox model. No significant association between antiviral agent and the risk of HCC and all-cause mortality was found even after adjusting for differences in baseline characteristics using IPW (Table [S12](#MOESM1){ref-type="media"} and Fig. [S4C,D](#MOESM1){ref-type="media"}).

Discussion {#Sec7}
==========

In our study, SVR achieved with antiviral treatment including IFN-based therapy and DAAs was associated with a reduced risk of developing HCC. The risk of HCC development was significantly lower by 84% in patients who achieved SVR with antiviral treatment compared with untreated patients. The association between SVR and the risk of HCC was evident among patients with intermediate- or high-probability of significant hepatic fibrosis (i.e., FIB-4 ≥ 1.45) at baseline. In addition, we demonstrated an association between SVR achieved with treatment and prolonged overall survival, especially among patients with high-probability of significant hepatic fibrosis (i.e., FIB-4 ≥ 3.25) at baseline. DAA-induced SVR was not associated with increased risk of HCC and overall death compared with SVR achieved with IFN-based therapy.

We identified the beneficial impact of SVR on the risk of HCC development according to stratified probabilities of significant fibrosis based on a noninvasive marker, the FIB-4 score. We observed increasing risk of HCC in proportion to baseline FIB-4 scores. Additionally, SVR was associated with a relatively less reduction of HCC risk among patients with high-probability of significant hepatic fibrosis (adjusted HR, 0.243; 95% CI, 0.107--0.551) than among patients with intermediate-probability of significant hepatic fibrosis (adjusted HR, 0.171; 95% CI, 0.051--0.578), suggesting the beneficial effect of earlier treatment initiation before progression to advanced fibrosis or cirrhosis. A previous study using the US Veterans Administration database showed early treatment before FIB-4 reaching 3.25 was more beneficial than deferring treatment after FIB-4 exceeding 3.25 in terms of mortality and liver-related morbidity^[@CR21]^. Although effect of SVR on mortality and liver-related morbidity by fibrosis stage cannot be assessed clearly because data on SVR achievement with treatment are not available in the previous report, the study results are supportive of our present study.

Assessment of liver disease severity prior to antiviral therapy is mandatory for the prediction of treatment response and long-term outcomes^[@CR2],[@CR4]^. FIB-4, an accurate, inexpensive, and noninvasive marker of hepatic fibrosis in HCV-infected patients, has the strong advantage of availability to all clinical practitioners, even in developing countries where medical resources are limited^[@CR22]^. Accordingly, FIB-4 is recommended as one of the most useful noninvasive tests for assessing the severity of liver disease by the current international guideline^[@CR2]^. A FIB-4 score \< 1.45 showed a negative predictive value for the exclusion of severe fibrosis (≥F3) of 94.7%, while a score ≥ 3.25 had a positive predictive value of 82.1% to confirm severe fibrosis^[@CR22]^. In our study, SVR was associated with reduced risk of all-cause mortality and HCC among patients with high-probability of significant fibrosis at baseline, these findings were consistent with the previous reports^[@CR15],[@CR16]^. A recent study conducted by Yu *et al*. showed that non-SVR was an independent predictor of HCC development in patients with METAVIR fibrosis grade F2--F3 or F4 but not in those with F0--F1^[@CR23]^. Although that previous study included only patients receiving IFN-based therapy, the results are generally consistent with our present study. Moreover, we additionally demonstrated that patients with high-probability of significant fibrosis were not at low risk of developing HCC, even if they receive antiviral treatment and achieve SVR. The 5-year cumulative incidence rate of HCC was 12.3% in the SVR group among patients with high-probability of significant fibrosis at baseline, as distinguished from extremely low rate in the SVR group among patients with low- or intermediate-probability (i.e., FIB-4 \< 3.25). Consequently, prompt treatment initiation is absolutely indicated for patients with high-probability of significant fibrosis and these patients need to undergo ongoing surveillance for HCC even after achieving SVR, given that their estimated HCC risk exceeds the thresholds (0.8--1.5% per year) for cost-effectiveness of HCC surveillance^[@CR2]--[@CR4],[@CR24],[@CR25]^. Kanwal *et al*. recently reported that annual incidences of HCC ranged from 1.0% to 2.2% among virologically cured patients with cirrhosis diagnosis^[@CR11]^. Moreover, HCC risk was not low (2.16% per year) in patients with a high baseline FIB-4 (\>3.25) in that study. In contrast, it was determined that successful HCV eradication diminished and nearly eliminated the risk of HCC in patients with low- or intermediate-probability of significant fibrosis in our present study, thus further studies to investigate whether these patients should remain under regular surveillance for HCC are warranted.

In our current study, we demonstrated that patients who achieved SVR with antiviral treatment faced reduced risk of HCC (84%) and all-cause mortality (85%) than untreated patients. In the secondary analysis involving patients in whom SVR was achieved with antiviral treatment, it was found that DAA-induced SVR was not associated with higher risk of HCC and overall death compared with SVR induced by IFN-based therapy. These findings are consistent with a recent study conducted by Ioannou *et al*. using the US Veterans Administration cohort^[@CR12]^. Although that previous study only included treated patients and compared the risk of HCC between the SVR group and the non-SVR group, SVR was associated with a 61% reduction in HCC risk compared with treatment failure. Furthermore, the risk reduction of HCC associated with SVR was similar regardless of treatment regimen (DAA-only, DAA + IFN, or IFN-only), leading to the conclusion that there was no evidence supporting the hepatocarcinogenic effect of DAA therapy. However, because the follow-up period of patients treated with DAAs was relatively short compared to that of patients treated with IFN-based therapy, long-term comparative studies are warranted.

An untreated control group was included in our present study to clearly assess the effect of antiviral treatment on the risk of HCC and mortality. However, substantial bias inherent in this approach should be concerned. The untreated patients might be less likely to be diagnosed with HCC than the treated patients because of lower compliance to HCC surveillance. Considering this possible ascertainment bias, the actual cumulative HCC incidence curves are presumed to further diverge than those of the current study. Moreover, we took into account the inevitable selection bias resulting from the nature of retrospective observational study design, and differences in some baseline characteristics between the groups were observed indeed. Thus, we performed rigorous adjustment for confounding factors by means of employment of IPW to reduce the treatment selection bias.

Our study has several limitations. First, since this was a retrospective study, we could not obtain data on metabolic features of the study subjects, such as body mass index and the presence of dyslipidaemia. However, given that the presence of diabetes mellitus or hypertension was not significantly associated with HCC development or overall death in our study, it is unlikely that other metabolic features had a considerable impact on the study results. Second, owing to missing values of certain baseline characteristics for calculation of propensity scores in a considerable number of patients, the sample size for IPW analysis became relatively small. Nevertheless, the analyses before and after IPW were generally consistent. Third, the follow-up period of patients treated with DAAs was not long enough to assess long-term effects of DAA-induced SVR. While the SVR effect on the risk of HCC and mortality was not found among patients with low-probability of significant hepatic fibrosis (FIB-4 \< 1.45) in our present study, it may become evident with accumulation of clinical events over time^[@CR26]^.

In summary, reduced risk of developing HCC and all-cause mortality was observed in patients with chronic HCV infection achieving viral eradication with antiviral treatment including IFN-based therapy and DAAs, and the beneficial effect of SVR on the risk of HCC was verified in patients with intermediate- or high-probability of significant fibrosis (FIB-4 ≥ 1.45). However, since SVR was not directly linked to complete prevention of HCC development in patients with high-probability of significant hepatic fibrosis, regular HCC surveillance may be necessary in these patients. In addition, we found that patients achieving SVR with DAA therapy were not at higher risk of HCC and overall death compared with patients achieving SVR with IFN-based therapy.

Patients and Methods {#Sec8}
====================

Study population {#Sec9}
----------------

The study population was obtained from inpatient and outpatient database files between January 1, 2006 and January 31, 2017 at Seoul National University Hospital (Seoul, Korea) and consisted of a cohort of 1,899 consecutive CHC patients positive for both HCV antibody (anti-HCV) and serum HCV RNA (Fig. [S5](#MOESM1){ref-type="media"}). Exclusion criteria were (1) history of malignant disease including HCC; (2) prior liver transplantation; (3) co-infection with hepatitis B virus or human immunodeficiency virus; (4) history of chronic kidney disease or heart failure; (5) hepatic decompensation; (6) follow-up duration of less than 6 months; and (7) diagnosis of HCC within 6 months of follow-up. Consequently, a total of 1,373 patients were included in the final analyses.

Patients in the treated group were treated with IFN-based regimens including standard and pegylated IFN with or without ribavirin (but without any of DAAs) or DAAs with or without ribavirin. SVR was defined as undetectable serum HCV RNA level by the Abbott Real-Time PCR HCV assay (Abbott Molecular Inc., IL, USA) with a lower limit of detection of 12 IU/mL at least 12 weeks post-treatment^[@CR27]^. Patients in the untreated group were not treated due to unwillingness to receive antiviral treatment with concern about high cost and possible drug-drug interactions of DAA-based treatment or low SVR rates and side effects of IFN-based treatment.

Patients were grouped into three groups: the untreated group; the non-SVR group; and the SVR group. FIB-4 scores, a simple noninvasive fibrosis scoring system, were calculated using the following formula: age (years) × aspartate aminotransferase (AST) (U/L)/\[platelets (10^9^/L) × \[alanine aminotransferase (ALT) (U/L)\]^1/2^\], and patients were categorised into the following subgroups according to FIB-4 scores at baseline: \< 1.45, low-probability of significant fibrosis, *n* = 258; 1.45--3.25, intermediate-probability, *n* = 492; and ≥ 3.25, high-probability, *n* = 446^[@CR22]^.

The study conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki and was approved by the Institutional Review Board of Seoul National University Hospital. The requirement for written informed consent was waived, because clinical data were analysed anonymously.

Clinical outcome measures {#Sec10}
-------------------------

The primary outcome was the development of HCC during the observation period. The secondary outcome was all-cause mortality. The index date was defined as the first date that a patient was found to have a positive anti-HCV test for the untreated group and the date of treatment initiation for the treated group regardless of SVR achievement. Most study subjects underwent surveillance for HCC with abdominal imaging and/or alpha-fetoprotein. Diagnosis of HCC was established based on guidelines of the American Association for the Study of Liver Diseases^[@CR24],[@CR28]^. All image scans were reviewed by two radiologists (L.J.M. and L.D.H.) with \>10 years of experience who were unaware of the clinical information for the study patients. An additional independent experienced radiologist reviewed radiological images in cases of discordance. If diagnosis was not established radiologically, we performed liver biopsy for histological diagnosis of HCC.

Statistical analysis {#Sec11}
--------------------

For the primary analysis, the baseline demographic and clinical characteristics were compared among the three groups of study subjects. For group-wise comparisons, one-way analysis of variance or the Kruskal-Wallis test was used for continuous variables, and either the χ^2^ test or the Fisher's exact test was performed for categorical variables. The Mantel-Byar method was applied to correct immortal time bias^[@CR29],[@CR30]^. If the date of anti-HCV testing and the date of treatment initiation were more than 6 months apart in treated patients, the time between the two time points was regarded as "untreated" and "treated" thereafter. In the time-to-event analysis, if patients in the untreated group started antiviral treatment, patients were censored at the date of initiation of antiviral treatment. If patients who had failed to achieve SVR with IFN-based therapy (the non-SVR group) were retreated with DAA therapy, patients were censored at the date of initiation of DAA therapy. Patients lost to follow-up before the diagnosis of HCC were censored at the date of the last surveillance for HCC in the time-to-HCC development analysis, whereas patients were not censored except in case of aforementioned patient censoring in the time-to-all-cause mortality analysis. Times to events and cumulative incidences were calculated using the Kaplan--Meier method and compared by the log-rank test. The treatment effect on occurrence of HCC and all-cause mortality was assessed using the Cox proportional hazards regression model. Subgroup analyses were conducted to further investigate the impact of SVR.

Inverse probability weighting (IPW) based on propensity score that estimated the probability to be treated and achieve SVR was applied to correct baseline differences among the three groups^[@CR31],[@CR32]^. A propensity score for each patient was calculated using a logistic regression model including the baseline demographic and clinical characteristics as described previously^[@CR33]^. The baseline characteristics between the groups were more balanced after IPW, and we fitted weighted Cox models thereafter.

For the secondary analysis, the patients who achieved SVR were divided into two groups according to type of antiviral regimen (IFN-based therapy or DAA therapy). The baseline characteristics were compared between the two groups and the effect on the risk of HCC and mortality was evaluated. We re-calculated propensity score of each patient reflecting the probability to be treated with DAAs and performed IPW, and then, survival analyses were repeated.

All statistical tests were conducted as two-sided tests, and a *P* value less than 0.05 was considered statistically significant. R language version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria) and SAS software version 9.4 (SAS Inc., Cary, NC, USA) were used for all statistical analyses.
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